EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Azithromycin Protects Oligodendrocyte Progenitor Cells against Lipopolysaccharide-Activated Microglia-Induced Damage

Sumana Ramarao, Yi Pang, Kathleen Carter, Abhay Bhatt

Developmental Neuroscience · 2022 · 44 (1) · 1-12

DOI: 10.1159/000519874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Developmental Neuroscience, online erschienen am 27.09.2021. Verfasst von Sumana Ramarao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Newborn Medicine, Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi, USA. Hauptthemen laut MEDLINE: Lipopolysaccharides, Oligodendrocyte Precursor Cells. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligodendrocyte progenitor cells (OPC) are the primary cellular targets of brain white matter injury (WMI) in very low-birth weight (VLBW) infants. Microglia plays a significant role in inflammation-induced WMI. Our previous study showed that lipopolysaccharide (LPS)-induced OPC damage is mediated by activated microglia in vitro. We hypothesized that azithromycin (AZ) could protect OPCs against LPS-induced cytotoxicity by blocking microglial activation. Highly enriched primary rat microglia and OPCs were treated with LPS. There were 4 groups: control, LPS + Veh, AZ, and LPS + AZ. Microglia conditioned medium (MCM) was used to determine inflammatory cytokines by enzyme-linked immunosorbent assay or subsequent treatment of OPCs. We found that AZ significantly suppressed TNF-α, IL-1β, and IL-6 in LPS+Veh-treated–microglial MCM and blocked microglial nuclear factor-κB p65 nuclear translocation. AZ prevented LPS-MCM-induced OPC death and improved OPC survival as measured by activated caspase-3 immunostaining and XTT assay, respectively. AZ ameliorated LPS-MCM-induced differentiation arrest and myelin basic protein deficit in oligodendrocytes. Our data suggest that AZ is a potent inhibitor for microglia activation and may hold the therapeutic potential for WMI in VLBW infants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipopolysaccharidesOligodendrocyte Precursor CellsAnimalsAzithromycinHumansMicrogliaOligodendrogliaRats

Stichwörter der Autor:innen

Encephalopathy of prematurityNeuroinflammationNeuroprotectionVery low-birth weight infantsWhite matter injury

Substanzen

LipopolysaccharidesAzithromycin

Autor:innen und Institutionen

  • Division of Newborn Medicine, Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi, USA.

Zitieren

APA

Ramarao, S., Pang, Y., Carter, K., & Bhatt, A. (2022). Azithromycin Protects Oligodendrocyte Progenitor Cells against Lipopolysaccharide-Activated Microglia-Induced Damage. Developmental Neuroscience, 44(1), 1-12. https://doi.org/10.1159/000519874

Vancouver

Ramarao S, Pang Y, Carter K, Bhatt A. Azithromycin Protects Oligodendrocyte Progenitor Cells against Lipopolysaccharide-Activated Microglia-Induced Damage. Developmental Neuroscience. 2022;44(1):1-12. doi:10.1159/000519874

BibTeX
@article{Ramarao2022,
  author = {Ramarao, Sumana and Pang, Yi and Carter, Kathleen and Bhatt, Abhay},
  title = {Azithromycin Protects Oligodendrocyte Progenitor Cells against Lipopolysaccharide-Activated Microglia-Induced Damage},
  journal = {Developmental Neuroscience},
  year = {2022},
  volume = {44},
  number = {1},
  pages = {1--12},
  doi = {10.1159/000519874}
}
Kostenlos starten →